PureTech appoints Kiran Mazumdar-Shaw to board of directors

She is a recipient of several national honours including the Padma Shri (1989) and Padma Bhushan (2005), two of India’s most prestigious civilian awards

Ms Shaw is the founder and chairperson of Biocon Limited. She brings extensive experience in biotherapeutics, strategic leadership, financial and business development and a dedication to improving patients’ lives to PureTech’s board of industry leaders.

In addition to her leadership of Biocon, Ms Shaw chairs the Indian State of Karnataka’s Vision Group on Biotechnology and is on the Advisory Council of the Indian government’s Department of Biotechnology. She serves on the Board of Trustees at Massachusetts Institute of Technology (MIT) and the Keck Graduate Institute (KGI). She is an independent director on the board of Infosys and Narayana Health, and is also an elected international member of the prestigious US National Academy of Engineering (NAE).

“I am thrilled to join the luminaries on PureTech’s board at a time when the company is poised for rapid growth building on the many successes of recent years,” Ms Shaw said. “With a unique and extremely productive approach towards the development of new medicines, the PureTech team has developed an impressive track record of pioneering new therapies, all of which could be transformational across a number of fields. With exciting programmes within its Wholly Owned Pipeline, PureTech has the potential to be truly disruptive in addressing serious diseases where there is significant need.”

“Kiran is an entrepreneur and visionary who is credited with the conception, development and success of a highly respected and important biopharma enterprise,” said Daphne Zohar, founder and chief executive officer of PureTech. “Her proven track record of entrepreneurial ingenuity and integrity along with her demonstrated business leadership position her as an excellent addition to PureTech’s board of industry leaders. We are excited to work with her as we continue on our growth trajectory.”

On joining the board, Ms Shaw will become a member of the board's Remuneration and Nomination Committees.

Companies